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There are several kinds of epigenetic networks in the human body including the cell differentiation epigenetic network (DiEN) 
and the host adaptation epigenetic network (AdEN). DiEN networks are static and cell/tissue-specific. AdEN networks are varia-
ble and dependent upon environmental factors. DiEN and AdEN alterations can respectively serve as biomarkers for different 
kinds of diseases. Cancer is a consequence of accumulated pathophysiological adaptations of tissue stem cells to exposure of en-
vironmental carcinogens. Cancer cells are de-differentiated cells that obtain the capacity of unrestricted proliferation, local inva-
sion, and distant migration/metastasis. Both DiEN and AdEN changes can be observed in cancer tissues. Alterations of DNA 
methylation are the most stable epigenetic modifications and can be sensitively detected in a small cell population. These ad-
vantages make DNA methylation the optimal biomarkers for detection of initiated cells in precancerous lesions and metastasis 
stem cells in cancer tissues. It has been proven that p16 methylation can be used as a diagnostic biomarker to determine malignant 
potential of epithelium dysplasia in many organs including the stomach. In a large-scale validation study on the DNA methylome 
of gastric carcinomas (GC), the methylation status of more than 90 CpG islands has been analyzed by DHPLC. Furthermore, 
GFRA1 demethylation and methylation of SRF and ZNF382 are frequent events during gastric carcinogenesis and consistently 
correlate to GC metastasis and overall survival of GC patients from China, Japan, and Korea, respectively. In a population study, 
it has been demonstrated that gradual increasing of plasma miR-211 and other miRNA levels may be an early risk predictor for GC 
development. 
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1  Differentiation and adaptation epigenetic 
modifications 
There are several kinds of epigenetic networks in the human 
body, including the cell differentiation epigenetic network 
(DiEN) and the host adaptation epigenetic network (AdEN). 
DiEN networks are stable and cell/tissue-specific. AdEN 
networks are variable and dependent upon environmental 
factors. DiEN and AdEN alterations can respectively serve 
as biomarkers for different kinds of diseases. Epigenetic 
modifications and their composition patterns are diverse and 
complex in the body. It is the diversity that provides the 
necessary machinery needed to drive embryo stem cells to 
differentiate into about 210 distinct cell types in the body 
and enables the body to adapt efficiently to different envi-
ronmental factors [1–3]. The complexity of epigenetic net-
works also becomes one of the main obstacles for basic and 
translational research on epigenetics. On one hand, the 
complexity and diversity of epigenetic networks constitute 
endless research points. On the other hand, there are nu-
merous pathways/molecules driving the mechanisms of car-
cinogenesis and other pathogenesis that could be used to 
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develop novel molecular stratification systems for various 
diseases, therapeutic strategies, and drug design. 
Cancer is a consequence of accumulated pathophysio-
logical adaptations of tissue stem cells to exposure of envi-
ronmental carcinogens. Cancer cells are reprogrammed cells 
with the capacity of unrestricted proliferation, invasion, and 
metastasis. Therefore, both types of epigenetic changes can 
be observed in cancer tissues. Although modern epigenetic 
research began only 15 years ago, several clinical applica-
tions have already originated from epigenetic studies. For 
example, epigenetic modulators, including DNA methyla-
tion inhibitor 5-aza-deoxycytosine and histone deacetylase 
inhibitors vorinostat or romidepsin, have recently been ap-
proved by the FDA for patients with myelodysplasia syn-
drome and cutaneous or peripheral T-cell lymphoma, re-
spectively. Developments of DNA methylation biomarkers 
(Septin9, p16 [cdkn2a], MGMT) for cancer diagnosis and 
prediction of chemotherapy sensitivity are currently under 
clinical trials [4]. More application products will originate 
from epigenetic research if we can screen out and sub-classify 
the disease-related epigenetic modifications from the com-
plex epigenetic networks for translational practices. 
Differentiation states of somatic cells are almost lifetime- 
consistent. Thus, basic differentiation epigenetic networks 
(DiEN) should be lifetime-consistent. The stable DiEN 
networks are cell/tissue-specific and environmental factor- 
independent. In contrast, the adaptation epigenetic networks 
(AdEN) are local/systemic reactions and environmental 
factor-dependent. In fact, the epigenetic alteration profiles 
in pathological lesions are also disease-specific. DiEN dis-
orders may play a driving role in the development of dis-
eases related to disorders of cell differentiation, and thus 
become potential diagnosis biomarkers or therapeutic targets 
in these diseases. The differentiation-related diseases in-
clude cancers and precancerous lesions with cell de-differ-     
entiation, psoriasis and Alzheimer’s disease with cell over- 
differentiation, intestinal/squamous metaplasia and endo-
metriosis with cell trans-differentiation, and cell degenerat-
ing diseases (diabetes, cataract, vitiligo, aplastic anemia). 
AdEN modifications represent long-term biological re-
sponses of host cells to exposure of environmental factors. 
They can be employed to detect the host’s susceptibility to 
environmental factors and predict sensitivity of disease to 
chemical and physical therapies. Although the DiEN-AdEN 
classification of epigenetic networks may significantly im-
prove the efficiency of translational research, the concept 
using a corresponding class of epigenetic modifications as 
biomarkers for disease has not been well recognized. 
In addition, due to the cell/tissue-specificity of DiEN 
networks, tissue/organ samples have to be used in determi-
nation of DiEN biomarkers for the corresponding diseases. 
Surgically resected tumor tissues or tissue biopsies are op-
timal biological samples for analysis of epigenetic bi-
omarkers. It is well recognized that cancer stem cells in 
precancerous/cancer tissues should contribute to cancer de-
velopment, metastasis, recurrence, and formation of drug 
resistance. However, because the changes of gene expres-
sion occur in a limited number of stem cells, their visibility 
would be greatly reduced by the co-existent main cell pop-
ulations in which the gene expression has not changed. 
Therefore, detection of alterations of gene expression in 
these stem cells is very difficult with regular gene expres-
sion assays such as immunostaining, western blot, RT-PCR, 
and northern blot. The methylation status of CpG islands 
around transcription start sites represents the possibility for 
a particular gene to undergo transcription. Notably, methyl-
ated and demethylated CpG islands can be analyzed with 
methylation- and demethylation-specific assays, respective-
ly. This makes the detection of CpG island methylation sta-
tus so sensitive that methylation alterations that occur in a 
few cells from a particular tissue (about 0.1% of cell popu-
lation) can be clearly displayed. Furthermore, DNA methyl-
ation can be preserved in various samples stored in a 
wide-range of conditions (fresh/frozen or paraffin-embedded 
tissue blocks, free DNA in plasma, detached cells in gastric 
juice, sputum, urine, stool samples, and other body fluids). 
These advantages make DNA methylation an optimal bi-
omarker for cancer prevention, diagnosis, and tailored 
treatment [4]. Epithelial dysplasia is the main precancerous 
lesion in many organs in the body. We have proven that 
methylation of p16, the G1→S conversion checkpoint gene 
in the cell cycle, is a powerful biomarker for predicting ma-
lignant transformation of epithelial dysplasia [5,6]. This has 
been consistently confirmed by a number of independent 
studies in different countries [7–9]. Recently, we have de-
veloped a p16-specific probe-based quantitative MethyLight 
assay for the development of a p16 methylation diagnosis 
kit [10]. 
2  Current status of DiEN and AdEN network 
research 
Various high-throughput platforms used in ‘omics’ analysis 
are revolutionary tools for biological and medical research. 
Combined with bioinformatic analysis software and con-
cepts on systemic biology, the high-throughput data enables 
us for the first time to see biological activities in the body 
from a 4D (3 dimensions and time) perspective [3]. However, 
because of the limited human and financial resources avail-
able for research, it is impossible to validate the huge 
amount of raw data that flows out daily from these plat-
forms. The most frequent method of analysis for these om-
ics data for scientists is to carry out bioinformatic analysis, 
validate a few genes, and write a manuscript for publication. 
About 2% of DNA sequences in the human genome encode 
proteins. Protein-encoding genes include housekeeping genes, 
tissue-specific genes, and biotransformation/adaptation genes. 
The ENCODE project has provided huge amount of valuable 
data on various epigenomes [3]. At present, it is not well 
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defined what gene set corresponds to cell differentiations 
and what gene set corresponds to adaptations. It is not clear 
what gene expression changes relate to pathogenesis and 
can be used as biomarkers either. Although there is still 
much omics research work that needs to be done, we have 
begun to dissect various epigenetics activities from the 
networks’ point of view. 
A number of high-resolution epigenomes in the ENCODE 
project have been reported recently [3]. Lister et al. [11] and 
Laurent et al. [12] have respectively reported DNA methy-     
lomes at the single-base resolution in human embryo stem 
cells and the differentiated fetal or neonatal lung fibroblast 
cells using second-generation deep bisulfite-sequencing. 
Chodavarapu et al. [13] has studied the genome-wide rela-
tionship between DNA methylation and nucleosome posi-
tioning in a human embryo stem cell line and Arabidopsis 
thaliana. Using chromatin immuno-precipitation (ChIP) 
enrichment technologies, Barski et al. has generated high- 
resolution maps for the genome-wide distribution of 20 his-
tone lysine and arginine methylations as well as histone 
variant H2A.Z in human blood CD4+ T cells [14]. These 
genome-wide high-resolution data are important resources 
for investigations of DiEN networks. Using these databases, 
scientists can get preliminary information on DiEN net-
works in individual chromatin regions throughout the whole 
genome of these cell types. Multiple epigenomes and RNA 
transcriptomes in more normal cell types need to be se-
quenced to explore cross-talk between different types of 
epigenetic modifications in various intragenic and intergenic 
non-coding regions in the genome [15,16]. Differences in 
the epigenomes between different cell types are important 
clues for investigating the functions of the 98% non-coding 
regions in the genome. Comparison studies on epigenetic 
networks in normal tissues with pathological lesions are 
also essential for translational research. 
DNA methylation is the most stable epigenetic modifica-
tion. Recent studies have shown that the status of DNA 
methylation at some regions in the gene body may be the 
consequence of a dynamic balance between methylation and 
hydroxymethylation or demethylation [17–19]. Moreover, 
rather than being actively transcribed or completely silenced, 
many genes are transcribed at different levels in tissues. 
Methylation contributes to these transcriptional differences 
between tissues is often observed in CpG island shores 
(DNA sequences near CpG islands), but not in the core CpG 
islands around the transcription start sites [20,21]. Estab-
lishment of de novel DNA methylation in vivo involves 
multiple processes. DNA methylation is initiated at one side 
of the CpG islands and then extended into the core region 
[22–24]. Our studies have shown that nucleosomes in tumor 
suppressor genes (p16, spint2, and hMLH1) may be the 
basic units for extension of de novel DNA methylation and 
demethylation in both cell lines and gastric tissues. We 
suggest that most CpG sites in the same nucleosomal DNA 
may be methylated/demethylated simultaneously, then ex-
tended to its flanking nucleosome one by one [24,25]. This 
is consistent with the recent genome-wide study that DNA 
methylation in an embryo stem cell line correlates to nucle-
osome positioning [13]. In studies of alterations of DNA 
methylation as cancer markers, methylation of crucial CpG 
sites inversely correlated with inactivation of gene tran-
scription should be characterized and used to represent in-
activation status of the gene by DNA methylation. Detec-
tion of methylation in these CpG sites for more than one 
nucleosome DNA may be necessary, if possibk, during the 
development of methylation biomarker kits. 
Notably, the stability of DNA methylation is gene or nu-
cleosome-dependent. For example, p16 inactivation by 
methylation in cancer cells is very stable. Methylation of 
p16 CpG islands can be gradually restored within about 
two-weeks after demethylation induced by DNMT1 inhibi-
tor treatment, with or without combined treatment of HDAC 
inhibitor [26]. After the p16-methylated cell line AGS is 
fused with the p16-unmethylated cell line MGC803, we find 
that the methylation status of p16 CpG islands is very con-
sistent in fusion cells. Most p16 alleles from the AGS cells 
are methylated, while p16 alleles from the MGC803 cells 
are not methylated in the fusion cells. This is similar to p16 
hemi-methylation in HCT116 cells in which the mutant p16 
alleles are not methylated and the wildtype alleles are meth-
ylated. In contrast, the methylation stability of Spint2 is 
nucleosome-dependent. The Spint2 CpG island is com-
pletely methylated in MGC803 cells and not methylated in 
AGS cells. Interestingly, all Spint2 alleles in the fusion cells, 
whether from MGC803 or AGS, are fully demethylated at 
two 5′UTR nucleosomes, but completely methylated at the 
exon-1 coding nucleosome from MGC803 derived alleles 
(Lu Z M, et al., unpublished data). Both p16 and Spint2 are 
actively expressed in the fusion cells. Therefore, character-
ization of methylation stability of candidate genes in cancer 
cells and its associations with differentiation/adaptation is 
also a key issue in translational research [27]. 
Some association studies have been reported on the po-
tential clinical application of using global levels of certain 
types of histone modifications in tissue samples. Changes of 
histone modifications in tissues may be used as biomarkers 
for the prediction of prognosis of cancers. However, it is 
unknown how these histone modifications affect behavior 
of cancer cells and the clinical outcomes of cancer patients. 
Combination of ChIP and genome-wide deep sequencing 
may be a powerful tool able to characterize their target 
genes/loci and related epigenetic networks in cancer tissues. 
Differential methylation hybridization using CpG island 
microarray and restriction landmark genome scanning 
(RLGS) are two first generation assays for detection of 
DNA methylomes of tissue or cell samples. These assays 
can be conveniently used to screen methylation differences 
between tissue samples. These array studies reveal that the 
alterations of DNA methylation have non-random and tis-
sue- and tumor type-specific patterns [20,28]. These plat-
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forms are also frequently used to characterize the methylation 
differences in the genomes related to development and 
prognosis of cancers [29–31]. Because of low detection 
sensitivity and limited cell number, alterations of methyla-
tion in CpG islands that occurred in cancer stem cells could 
not be detected using these array-scanning assays. It is al-
most impossible to validate the numerous methylation alter-
ations with precise bisulfite-sequencing due to time/cost 
constraints. Because of the lack of information on the dis-
tribution of methylated CpG sites in the candidate CpG is-
lands, the feasibility and efficiency to validate candidate 
methylation using CpG site-specific assays such as methyl-
ation-specific PCR (MSP), combined-bisulfite restriction 
assay (COBRA), MethyLight, etc are quite low. Consequently, 
almost all of the raw data generated from these arrays has 
not been confirmed yet. In the following paragraphs, we 
briefly introduce the progression of our large-scale valida-
tion study on the DNA methylome of gastric adenocarci-
nomas using a cheap, efficient, denatured high-performance 
liquid chromatography (DHPLC) method and investigation 
of epigenetic epidemiology on gastric carcinomas. 
3  Alterations of DNA methylation as biomarkers 
for metastasis of gastric carcinomas 
Cancer is a cell de-differentiation disease. It is a conse-
quence of carcinogen-induced pathophysiological adapta-
tions in normal cells. Malignant transformed cells are epi-
genetically reprogrammed with a decreased genetic stability. 
Cancer cells are capable of stimulating a series of epigenetic 
changes in the stromal cells that lead to angiogenesis and 
extracellular matrix degradation to favor tumor growth, in-
vasion, and metastasis. At the same time, the human body 
can make a series of local and systemic epigenetic adapta-
tions against cancer cells. 
Progression of precancerous lesions, cancer invasion, 
metastasis, chemosensitivity, or drug resistance are biological 
properties of cancer cells. Thus it is possible to determine 
these properties using biomarkers. Increased invasion and 
migration abilities of cancer cells and decreased defense 
ability of stromal cells to restrict cancer cells are two crucial 
steps in the process of metastasis. It is recognized that only 
part of the cancer stem cells in tumor mass are able to in-
vade, migrate, and colonize in distant organs or tissues. We 
hypothesize that alterations of DNA methylation in these 
metastatic stem cells can be sensitively detected and serve 
as good prediction markers for cancer metastasis. 
Using the methylated CpG island amplification in com-
bination with microarray (MCAM) [31], we analyzed the 
methylation status of the CpG islands in 6177 genes in the 
genome of 4 metastatic and 4 non-metastatic GCs and their 
corresponding surgical normal margin samples, respectively. 
Using differential data of normalized methylation signals 
between 8 GC and 8 normal samples, we have selected a set 
of candidate CpG islands based on significant differential 
methylation related to carcinogenesis for further validation. 
Similarly, using the differential data of tumor/normal signal 
ratios between 4 metastatic and 4 non-metastatic GCs, we 
have also selected a set of metastasis-related candidate CpG 
islands. From the list of candidate genes, CpG islands of 90 
genes were bioinformatically enrolled into further validation 
studies, if they (or their family members) could be involved 
in cell proliferation or migration [32]. 
It is well recognized that repressive effects of methyla-
tion of CpG sites in CpG islands on gene transcription is 
region-dependent. These CpG sites are called crucial CpG 
sites when their methylation correlates to complete inactiva-
tion of the corresponding genes. Generally, the crucial CpG 
sites may locate within a two-nucleosome region around 
transcription start sites. Because the crucial CpG sites are 
not characterized for most CpG island-containing genes, we 
used the DHPLC assay to validate alterations of the methyl-
ation status of all 90 genes. DHPLC is a convenient assay 
for quantifying the proportion of methylated CpG islands 
we established previously [33,34]. Like bisulfite sequencing, 
PCR products (400–1000 bp) of methylated and unmethyl-
ated CpG islands amplified with CpG-free primers are ana-
lyzed with this assay. These PCR products can be directly 
sequenced if further confirmation and characterization of 
key CpG sites are necessary. 
DHPLC assays are setup for the detection of methylation 
of all 90 CpG islands, respectively. Using these assays, we 
found the methylation of 15 genes (BMP3, BNIP3, ECEL1, 
ELK1, GFRA1, HOXD10, KCNH1, p16, PSMD10, PTPRT, 
SIGIRR, SRF, TBX5, TFPI2, ZNF382) are significantly re-
lated to gastric carcinogenesis. Of them, methylation-inac-     
tivation of SRF or ZNF382 and demethylation-activation of 
GFRA1 are not only related to the development of GC and 
other cancers, but are also consistently related to metastasis 
and overall survival of GC patients in these discovery, test-
ing, and international validation cohorts. These findings 
show that alterations in methylation of SRF, ZNF382, and 
GFRA1 CpG islands are potential biomarkers for the pre-
diction of GC metastasis [35–37]. It is necessary to study 
the feasibility of their clinical applications in prospective 
studies among cancer patients without baseline metastasis. 
In addition, we find that the methylation status of 9 miR 
CpG islands (miR-9-1, miR-9-3, miR-34b/c, miR-137, miR- 
193b/365a, miR-200b/200c/429, miR-210, miR-375, and 
miR-663) is significantly changed during gastric carcino-
genesis. miR-9-1 and miR-137 methylation are mainly de-
tected in GC samples, indicating they could be used as can-
cer-specific biomarkers. miR-9-1 methylation is also weakly 
associated with GC metastasis and patients’ overall survival. 
Notably, we found that the methylation status of these CpG 
islands is inversely and consistently correlated to transcrip-
tion of the corresponding mature miRNA level by quantita-
tive RT-PCR in a panel of cell lines in vitro. In gastric tissue 
samples, such inverse methylation-repression association 
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could also be observed for miR-9-1, miR-9-3, miR-137, and 
miR-200b. These results suggest that transcription of miR 
genes in the genome may be regularly regulated by the 
methylation status of CpG islands [38]. 
4  Progression of epigenetic epidemiology of 
gastric carcinomas 
H. pylori infection causes chronic gastritis, digestive ulcer, 
and gastric mucosa-associated lymphoid tissue (MALT) 
lymphoma. Because there are close relationships between 
chronic atrophic gastritis and GC, H. pylori infection is also 
considered as a risk factor of GCs. It has been reported that 
H. pylori infection induces alterations of methylation of 
many CpG islands through inflammatory factors [39,40]. 
The inflammatory factors may theoretically release from the 
local gastritis lesions to the bone marrow through circula-
tion. It is interesting to investigate if H. pylori infection 
leads to alterations of DNA methylation in both gastric 
mucosa and white blood cells (WBC). Using a high- 
throughput platform at Dr. Yongsong Kim’s Lab in Korea, 
we are comparing the DNA methylomes of gastric mucosa 
biopsies and peripheral blood WBC samples from gastritis 
patients before and after H. pylori eradication, respectively. 
The DHPLC assay will be used to validate the array data in 
more patients. 
There are a number of reports on alterations of plasma 
mature miRNA levels in advanced cancer patients. But it is 
uncertain whether these alterations can be detected in early 
cancer patients and subjects with precancerous lesions [4]. 
It is hypothesized that circulating miRNAs may release lo-
cally from cancer tissues or from other tissues/organs as 
systemic adaptations. To clarify the feasibility of using cir-
culating miRNA as early predictors for GC development, 
Song et al. have determined circulating miRNA profiles in 
serum samples from GC patients and gastritis controls en-
rolled in a prospective study [41]. Using a low-density 
miRNA array, they found that the average levels of 8 
miRNA (miR-221, miR-744, miR-376c, miR-191, miR-27a, 
let-7e, miR-27b, and miR-222) are significantly different 
between these patients in the training cohort (n=28) and 
testing cohort (n=136). Further analysis showed that the 
average miR-222 level is increased in gastric dysplasia pa-
tients, compared with gastritis patients without dysplasia. 
Notably, historical comparison of serial serum samples from 
20 GC patients (collected in 1989, 1992/1994, and 1999/ 
2003 before cancer diagnosis) shows that levels of serum 
miR-221, miR-744, and miR-376c had progressively in-
creased in these patients before GC diagnosis. However, 
increasing patterns of these miRNAs were not observed in 
gastritis control subjects. It is well recognized that it is dif-
ficult to detect cancer risk using single sample analysis data. 
Dr. Song’s work implies that dynamic changes of circulat-
ing miRNA levels might be one kind of useful predictor of 
cancer risk. 
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